FASPRO

Latest Posts

First and solely subcutaneous anti-CD38 remedy demonstrating potential to stop end-organ harm, and prolong...

Market

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) exhibits 51 % discount in threat of development to energetic a number of myeloma for sufferers with high-risk...